Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Compugen Ltd (CGEN) posted $3.8 million in Q3 2026 revenue, completed MAIA-ovarian enrollment with data due by Q1 2027, and holds $117.5 million in cash to fund operations into 2029.
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.
Gilead Sciences reported third quarter 2026 revenue of US$8.3b and raised full year product sales guidance, while also outlining a larger projected GAAP loss tied to sizeable acquired R&D charges and maintaining its quarterly dividend at US$0.82 per share. Alongside the earnings update, Gilead highlighted extensive HIV, liver disease and oncology data readouts, signaling heavy investment in long acting prevention, new treatment regimens and cell therapy that could reshape how its future...
Dr. Reddy's Laboratories (RDY) stock gains as the firm wins FDA nod for a generic targeting Yeztugo, an HIV PrEP therapy developed by Gilead (GILD). Read more here.
This is the newest page. Registered accounts read further back.